The Claim
In adults with obesity prescribed semaglutide, greater loss of lean mass over 3 months is associated with lower protein intake, older age, and female sex, and is independently linked to reduced improvement in blood glucose control as measured by HbA1c.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity taking semaglutide, those who lose more muscle mass over three months tend to have lower protein intake, are older, or are female, and also show less improvement in blood sugar control.
See the scientific wording
In adults with obesity prescribed semaglutide, greater loss of lean mass over 3 months is associated with lower protein intake, older age, and female sex, and independently linked to reduced improvement in blood glucose control, as measured by HbA1c, suggesting that muscle preservation may be critical for metabolic outcomes during weight loss with this medication.
When muscle mass decreases during weight loss, the body loses its main site for removing sugar from the blood after meals. This causes blood sugar to stay higher than it should, even when a medication like semaglutide is used. People who eat less protein, are older, or are women lose more muscle during this process, making their blood sugar harder to control.
What the research says
1 studyWhen obese adults take semaglutide and lose weight, those who eat less protein, are older, or are women tend to lose more muscle — and they also don’t see as much improvement in their blood sugar. This suggests keeping muscle helps control blood sugar better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.